Aplastic Anemia News and Research RSS Feed - Aplastic Anemia News and Research

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies. [More]
NewYork-Presbyterian/WCMC join new MDS Clinical Research Consortium

NewYork-Presbyterian/WCMC join new MDS Clinical Research Consortium

NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium. [More]
Fera introduces Sulfacetamide Ointment for conjunctivitis

Fera introduces Sulfacetamide Ointment for conjunctivitis

Fera Pharmaceuticals is pleased to announce the launch of Sulfacetamide Sodium Ophthalmic Ointment USP, 10%. [More]
UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans. [More]
Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases. [More]
UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9. [More]
UCB to present new data on Cimzia at ACG annual scientific meeting

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2. [More]
Colon cleansing can cause side effects like cramping, renal failure and death

Colon cleansing can cause side effects like cramping, renal failure and death

Colon cleansing - it's been described as a natural way to enhance well-being, but Georgetown University doctors say there's no evidence to back that claim. In fact, their review of scientific literature, published today in the August issue of The Journal of Family Practice, demonstrates that colon cleansing can cause side effects ranging from cramping to renal failure and death. [More]
Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy. [More]
Half-matched transplants widen donor pool for leukemia and lymphoma

Half-matched transplants widen donor pool for leukemia and lymphoma

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy. The finding means that nearly all patients in need of a transplant can find donors, according to Johns Hopkins scientists who participated in the trials. [More]
Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes. [More]
New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients. [More]
Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began. [More]
Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection. [More]
Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting. [More]
Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today. [More]
Prototype drug halts GVHD in mouse models of bone marrow transplantation

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows. [More]
Quebec reimburses VIDAZA for treatment of blood cancer

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec patients with serious blood cancers (intermediate-2 and high-risk myelodysplastic syndrome and acute myeloid leukemia) now have publicly funded access to a new innovative therapy, VIDAZA® (azacitidine). Following a priority review and subsequent positive recommendation from the Conseil du medicament, patients now have the potential to significantly extend survival. [More]
New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

Independent investigators reported today that patients with paroxysmal nocturnal hemoglobinuria who were treated long-term with Soliris (eculizumab) achieved survival comparable to that of an age- and gender-matched normal population. Findings from this investigator-led analysis were reported in an oral presentation today at the 52nd American Society of Hematology Annual Meeting and Exposition in Orlando. [More]
New analysis evaluates association between hemolysis, mortality in patients with PNH

New analysis evaluates association between hemolysis, mortality in patients with PNH

Alexion Pharmaceuticals, Inc. today announced the presentation of an analysis from the National Data Registry in South Korea that evaluated the association between hemolysis and mortality in patients with paroxysmal nocturnal hemoglobinuria. [More]